Manufacture of pharmaceutical preparations
INSULIFE AS
Revenue 2024
NOK 56,000
Operating profit
NOK −13.0m
Equity
NOK 22.1m
Incorporated
2020
Share capital
NOK 72,000
Key figures · 2024
Current ratio
0.88
Equity ratio
77.0%
Key figures over time · 2024
| Key figures | 2024 | Trend |
|---|---|---|
| Lønnsomhet | ||
| Operating margin (%%) | -23243.4% | |
| Net margin (%%) | -23030.0% | |
| Return on assets (%%) | -45.4% | |
| Likviditet | ||
| Current ratio | 0.88 | |
| Working capital | −654k | |
| Soliditet | ||
| Equity ratio (%%) | 77.0% | |
| Debt-to-equity ratio | 0.30 | |
Source: Biztrac.no · Data from the Brønnøysund Register Centre and the Norwegian Tax Administration · Last updated 15.06.2026.